The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The challenges that remain in the management of MPNs
In this video, Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, briefly outlines the challenges in managing patients with myeloproliferative neoplasms (MPNs), highlighting that there are a limited number of therapies available and that many unanswered questions surrounding disease biology remain. Additionally, with the high costs of novel treatments, their impact on progression-free survival will need to be proven. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So there remain continued challenges in managing patients with MPNs. We still have a limited number of therapies and we still have some key biological questions to answer that are important in us managing those patients. Specifically, why do patients progress? What are the biological underpinnings of that? How can we track that as we investigate all of these new therapies that are being developed...
So there remain continued challenges in managing patients with MPNs. We still have a limited number of therapies and we still have some key biological questions to answer that are important in us managing those patients. Specifically, why do patients progress? What are the biological underpinnings of that? How can we track that as we investigate all of these new therapies that are being developed. I’m very excited about the new therapies, yet we fly a little blind in terms of really predicting their impact on progression-free survival, overall survival, while we lack that. Additionally, when resources are constrained, therapies, of course, they are expensive. And as we look to the era of combination therapies, they’ll be doubly or triply as expensive. So I think there will be more burden on us to prove that we’re having an impact on progression-free survival and overall survival, both justifying their use, but also to really choose between them because we’re going to have hopefully numerous additional options.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
